With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for Covid-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of mild to moderate Covid-19 cases, while Cipla and Hetero have received approvals from the Drug Controller General of India (DCGI) to launch Remdesivir under the brand names Cipremi and Covifor respectively.
Cipla Ltd on Sunday announced the launch of Cipremi.
Dr Sanjay Rai, Professor